Bayer Logo Bayer Logo Bayer Logo Bayer Logo

Kovaltry

Get them to where they need to be

Kovaltry is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) for adults, adolescents and children of all ages.

Kovaltry_logo

Confidence in Kovaltry in clinical and real-world settings

Kovaltry is backed by Leopold studies that consisted of 193 PTPs (142 adults/adolescents and 51 pediatrics)1,2,3

Launched in 2016, Kovaltry has accumulated 13,753 patient-years of exposure* to 31 August 20194

Kovaltry SmPC

PTP, previously treated patient

*Patient years of exposure = International Units sold/annual dose per patient

References

  • Saxena K, Lalezari S, Oldenburg J, et al. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.Haemophilia. 2016;22(5): 706-712. Return to content
  • Kavakli K, Yang R, Rusen L, et al. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost. 2015;13(3):360-36. Return to content
  • Ljung R, Kenet G, Mancuso M, et al. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial Haemophilia. 2016;22(3):354-60. Return to content
  • Bayer Data on File. August 2019. Return to content